SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare receives CDSCO approval for NorUDCA Tablets

09 Aug 2025 Evaluate

Shilpa Medicare has received approval from the Central Drugs Standard Control Organization (CDSCO) for its Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, marking a major milestone in innovative NAFLD therapy in India. The approval reinforces Shilpa Medicare’s commitment to addressing unmet medical needs in hepatology through innovation and evidence?based solutions. This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD.

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India, addressing a significant unmet medical need. NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the world’s population (approximately 1.2 billion people) and impacting an estimated 188 million individuals in India alone. If not managed early, NAFLD may progress to non?alcoholic steatohepatitis (NASH) and severe liver complications, underscoring the urgent necessity for effective therapy. These results collectively demonstrate a significant improvement in both liver structure and function, confirming NorUDCA’s superior efficacy compared to placebo in NAFLD.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

407.25 2.35 (0.58%)
22-Apr-2026 12:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1663.20
Dr. Reddys Lab 1225.70
Cipla 1236.25
Zydus Lifesciences 928.85
Lupin 2314.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×